radalbuvir
Small moleculeexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2010 (NCT01260350)
Timeline
Indications
Mechanism of action
- RNA-directed RNA polymeraseINHIBITOR
RNA-directed RNA polymerase inhibitor
Thumb site II
- Genome polyproteinINHIBITOR
Genome polyprotein inhibitor
Hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitor
Thumb site II
Chemistry & pharmacology
Loading structure…
SMILES
CC1=CC[C@H](C(=O)N(c2cc(C#CC(C)(C)C)sc2C(=O)O)[C@H]2CC[C@](O)(CO[C@H]3CCOC3)CC2)CC1- Mol. weight
- 543.73 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3121539 ↗
Also known as
- gs-9669
- gs-9669
- gs-9669 tablets
- radalbuvir
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01984294 | Phase 2 | Oct 1, 2013 | Gilead Sciences |
| NCT01826981 | Phase 2 | Apr 1, 2013 | Gilead Sciences |
| NCT01805882 | Phase 2 | Jan 1, 2013 | National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) |
| NCT01431898 | Phase 1 | Sep 1, 2011 | Gilead Sciences |
| NCT01260350 | Phase 2 | Dec 1, 2010 | Gilead Sciences |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Gilead Sciences | For profit | 4 | 4 | 2 | 2010 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 2013 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2013 |
3 organizations
Page 1 / 1